Nurix Therapeutics

Small Molecules, Protein Degradation

NX-5948 Clin1a B-cell malignancies; NX-1607 Clin1a immuno-oncology; NX-0479 Clin0 rheumatoid arthritis, inflammatory diseases; 3 undisclosed programs RD undisclosed

Nurix Therapeutics is discovering and developing therapies that modulate protein levels to treat cancer. Proteins are the workhorse of a cell and can become overexpressed, underexpressed or over-activated in diseases like cancer. Nurix is addressing these diseases through ‘Targeted Protein Modulation’ that enables tuning of specific protein levels. This can be used to destroy disease-causing proteins or to inhibit protein degraders and raise the level of beneficial proteins. Discovery involves use of Nurix’s DELigase platform to identify small molecules that bind their collection of E3 ligases. Nurix has identified a CBL-B ligase inhibitor that they are using to create superior adoptive cell therapies which are entering clinical trials.